Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Vallejos (Ciudad Autónoma Buenos Aires, Argentina), J. Martinez (Ciudad Autónoma Buenos Aires, Argentina), F. Cabrera (Ciudad Autónoma Buenos Aires, Argentina), N. Mastandrea (Ciudad Autónoma Buenos Aires, Argentina), M. Pertuz (Ciudad Autónoma Buenos Aires, Argentina), Z. Marengo (Ciudad Autónoma Buenos Aires, Argentina), M. López Meiller (Ciudad Autónoma Buenos Aires, Argentina), V. Volberg (Ciudad Autónoma Buenos Aires, Argentina), R. Gómez Tejada (Ciudad Autónoma Buenos Aires, Argentina). Association of FVC/DLCO with pulmonary hypertension risk and interstitial disease in systemic sclerosis patients. 302

Member's Comments

No comment yet.

Related content which might interest you: Risk assessment in patients with systemic sclerosis and pulmonary arterial hypertension Source: Eur Respir J, 52 (4) 1801745; 10.1183/13993003.01745-2018 Year: 2018 Pulmonary hypertension in patients with interstitial lung disease Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011 Systemic inflammation and pulmonary hypertension in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 142s Year: 2007 Identifying early pulmonary arterial hypertension in patients with systemic sclerosis Source: Eur Respir J, 51 (4) 1800495; 10.1183/13993003.00495-2018 Year: 2018 Evaluation of FVC/DLCO ratio as a predictor for pulmonary hypertension in patients with interstitial lung diseases Source: International Congress 2017 – ILDs: clinical problems Year: 2017 Lung function and pulmonary hypertension in systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 548s Year: 2006 Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis Source: Eur Respir J, 51 (4) 1701197; 10.1183/13993003.01197-2017 Year: 2018 Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening Source: Eur Respir Rev 2011; 20: 270-276 Year: 2011 Pulmonary arterial manifestation of systemic inflammation in patients with COPD Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Systemic sclerosis associated with pulmonary arterial hypertension is most severe in African American patients Source: Annual Congress 2011 - Clinical features of pulmonary hypertension Year: 2011 Systemic inflammation in chronic obstructive pulmonary disease in patients with pulmonary hypertension Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 A screening protocol for pulmonary hypertension in systemic sclerosis identifies patients with pulmonary hypertension on exercise Source: Eur Respir J 2004; 24: Suppl. 48, 277s Year: 2004 Oxygen pulse slope analysis during exercise testing identifies patients with systemic sclerosis at a possible risk for developing pulmonary vasculopathy Source: Annual Congress 2013 –Clinical exercise physiology Year: 2013 Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Risk assessment in severe pulmonary hypertension due to interstitial lung disease Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Predictors of progression in systemic sclerosis patients with interstitial lung disease Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019 Year: 2020 Baseline characteristics and survival of patients with pulmonary hypertension in interstitial lung disease in the “HYPID” study Source: Annual Congress 2013 –Pulmonary circulation: clinical physiology Year: 2013 Biomarkers in pulmonary hypertension associated to interstitial lung disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Comorbidities in patients with the combined pulmonary fibrosis and emphysema syndrome (CPFE) Source: International Congress 2015 – Interstitial lung diseases II Year: 2015